Company: AEMD
Filing Date: 2025-09-05
Form Type: 424B4
Source: 0001683168-25-006701
Chunk: 7

Company: AETHLON MEDICAL INC
Filing Date: 2025-09-05
Form: 424B4
Chunk 7
---
iral infections and for use in organ transplantation. In human studies, 164 sessions with 38 patients, the Hemopurifier was safely utilized
and demonstrated the potential to remove life-threatening viruses. In pre-clinical studies, the Hemopurifier has demonstrated the potential
to remove harmful exosomes and exosomal particles from biological fluids, utilizing its proprietary lectin-based technology. This action
has potential applications in cancer, where exosomes and exosomal particles may promote immune suppression and metastasis, and in life-threatening
infectious diseases. The U.S. Food and Drug Administration, or FDA, has designated the Hemopurifier as a “Breakthrough Device”
for two independent indications:

| · | the treatment of individuals                                                                                                       
 with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types 
 in which exosomes or exosomal particles have been shown to participate in the development or severity of the disease; and          |
| · | the treatment of life-threatening                                                                                                  
 viruses that are not addressed with approved therapies.                                                                            |

Oncology

We believe that the Hemopurifier
may be a substantial advancement in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove
harmful remove harmful extracellular vesicles particles that promote the growth and spread of tumors. In October 2022, we formed a wholly-owned
subsidiary in Australia to initially conduct oncology-related clinical research, then seek regulatory approval and commercialize our
Hemopurifier in Australia.

We completed an in vitro binding
study of extracellular vesicles from cancer patient samples, to provide pre-clinical evidence to support our trial design and translational
endpoints. Our study indicated positive results from this study, providing evidence that our Hemopurifier removes extracellular vesicles,
or EVs, from plasma. This translational study provides pre-clinical evidence to support our phase 1 safety, feasibility and dose-finding
clinical trials of our Hemopurifier in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy
treatment, such as Keytruda® or Opdivo®.

We have launched in an Australia
safety, feasibility and dose-finding clinical trials of the Hemopurifier in cancer patients with solid tumors who have stable or progressive
disease during anti-PD-1 monotherapy treatment, such as Keytruda